阿玛琳 AMRN 深 沪
已收盘 08-01 16:00:00 美东时间
15.16
+0.640
+4.41%
华盛通- 最 高15.651
- 今 开14.24
- 成交量 8.85万股
- 最 低 14.05
- 昨 收 14.52
- 总市值 3.14亿
- 52周最高 17.49
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.08
- 委 比 -86.57%
- 总股本 2070.70万
- 历史最高 522.40
- 量 比 1.21
- 振 幅 11.03%
- 历史最低 7.08
- 每 手 1
- 风险率 1.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多苹果、微软、亚马逊、Meta财报来袭
作者丨Oliver Rodzianko 编译 | 华尔街大事件 本周科技巨头、能源巨头、金融公司、医疗保健行业领袖和消费者品牌将陆续发布大量财报。 焦点将集中...
07-28 20:40
Amneal to Report Second Quarter 2025 Results on August 5, 2025
Amneal Pharmaceuticals will release its second quarter 2025 financial results on August 5, 2025, before market open. A live audio webcast will be held at 8:30 a.m. ET, accessible via the company's Investor Relations website or by dialing 1 (833) 470-1428 with access code 627786. The company, headquartered in Bridgewater, NJ, specializes in developing, manufacturing, and distributing over 280 pharmaceuticals, with a focus on affordable medicines, ...
07-09 12:00
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
美股牛股 | 纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%
纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%，皮炎药物临床试验结果良好；安霸拟考虑出售公司，隔夜涨超20%>>
06-25 19:15
Amarin Enters Licensing Agreement with Recordati
Amarin ( ($AMRN) ) just unveiled an announcement. On June 20, 2025, Amarin Corp...
06-24 19:29
Market-Moving News for June 24th
INM: 102% | InMed shares are trading higher after the company announced preclinical data showing INM-901 reduced neuroinflammation markers in an ex vivo Alzheimer's disease study. NA: 108% | Nano Labs
06-24 19:16
Amarin Strikes $175M Deal With Recordati to Expand Heart Drug VAZKEPA Across 59 European Countries
Amarin Corporation (NASDAQ:AMRN) today announced that the Company has entered into an exclusive long-term license and supply agreement (the "Agreement") with Recordati S.p.A. ("Recordati") to commercialize VAZKEPA®
06-24 19:02
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
Amarin Corporation has entered into an exclusive long-term agreement with Recordati S.p.A. to commercialize VAZKEPA® (icosapent ethyl) in 59 European countries. This partnership aims to expand VAZKEPA's reach and strengthen Amarin's financial position, with cost savings of approximately $70 million over the next 12 months and accelerated positive cash flow. Amarin will receive $25 million upfront, potential milestone payments up to $150 million, ...
06-24 11:00
Amarin Shareholders Reject Key Proposal at AGM
Amarin ( ($AMRN) ) has issued an update. At Amarin Corporation’s Annual General...
05-16 05:44
